Whalesbook
Apotex ne ye generic semaglutide injection banaya hai Orbicular Pharmaceutical Technologies ke saath milkar. Ye pehla tentative approval hai US mein Ozempic ke generic version ke liye. Ab tak Novo Nordisk is multi-billion dollar market mein akela raja tha, par ye approval competition laayega aur shayad prices bhi kam karega. Patients ke liye ye bahut achhi khabar ho sakti hai.
Par itna aasan bhi nahi hai game. Semaglutide jaise complex peptide drug ko develop karna bahut mushkil hai, ismein precision aur strict methods chahiye. Yehi wajah hai ki generics ko approve hone mein time lagta hai. Tentative approval ka matlab hai ki drug quality, safety, aur efficacy standards pura karta hai, par actual market mein launch hone ke liye Novo Nordisk ke patents aur exclusivity ko hatana hoga. Ye patents lagbhag 2031-2032 tak hain, toh pura market mein aane mein abhi time hai.
GLP-1 drugs ka market toh waise hi tens of billions of dollars ka hai. Diabetes aur obesity ke badhte cases ke karan log ye drugs bahut use kar rahe hain. Novo Nordisk ka Ozempic aur Wegovy bahut paisa kama rahe hain. Lekin company ka stock bhi thoda gir raha hai, competition (Eli Lilly ke tirzepatide se) aur patent expiry ki wajah se. Generic semaglutide ka aana prices par pressure zarur dalega, jaise pehle liraglutide ke saath hua tha.
Abhi bhi challenges kam nahi hain. Apotex aur Orbicular ko final regulatory steps complete karne hain aur patent issues suljhane hain. Novo Nordisk apne patents ko defend karne mein kafi aggressive rehta hai. Peptide drugs ko bade scale par banana bhi ek bada challenge hai, aur supply issues se bachna hoga. Court cases aur payers ka approval bhi matter karega.
Lekin agar sab theek raha, toh ye tentative approval semaglutide therapies ko zyada accessible aur affordable banane ki taraf ek bada kadam hai. Patients ke liye out-of-pocket costs kam ho sakte hain. Pharmaceutical industry mein, especially metabolic diseases ke liye, ye ek bada transformation layega.